Antitumor activity of Herceptin® in combination with STEALTH® liposomal cisplatin or nonliposomal cisplatin in a HER2 positive human breast cancer model

Colbern, Gail; Hiller, Alan J.; Musterer, Randy; Henderson, I. Craig

doi:10.1016/s0162-0134(99)00138-5

Cited by 26 publications

(12 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The efficacy of crystalline trastuzumab was examined in a series of experiments conducted in nude mice bearing BT-474 xenografts (17). Crystalline suspensions of trastuzumab, given s.c. at doses from 1 to 30 mg͞kg (0.1 ml) twice a week for 4 weeks, induced a dose-dependent inhibition of growth of the BT-474 xenografts (Fig.…”

Section: Resultsmentioning

confidence: 99%

Crystalline monoclonal antibodies for subcutaneous delivery

Yang

Shenoy

Disttler

et al. 2003

Proc. Natl. Acad. Sci. U.S.A.

142

130

View full text Add to dashboard Cite

Therapeutic applications for mAbs have increased dramatically in recent years, but the large quantities required for clinical efficacy have limited the options that might be used for administration and thus have placed certain limitations on the use of these agents. We present an approach that allows for s.c. delivery of a small volume of a highly concentrated form of mAbs. Batch crystallization of three Ab-based therapeutics, rituximab, trastuzumab, and infliximab, provided products in high yield, with no detectable alteration to these proteins and with full retention of their biological activity in vitro. Administration s.c. of a crystalline preparation resulted in a remarkably long pharmacokinetic serum profile and a dose-dependent inhibition of tumor growth in nude mice bearing BT-474 xenografts (human breast cancer cells) in vivo. Overall, this approach of generating high-concentration, low-viscosity crystalline preparations of therapeutic Abs should lead to improved ease of administration and patient compliance, thus providing new opportunities for the biotechnology industry.

show abstract

Section: Resultsmentioning

confidence: 99%

Crystalline monoclonal antibodies for subcutaneous delivery

Yang

Shenoy

Disttler

et al. 2003

Proc. Natl. Acad. Sci. U.S.A.

142

130

View full text Add to dashboard Cite

show abstract

“…HA is used in clinical treatment due to its unique viscoelastic and hydrophilic properties along with its biocompatibility and nonimmunogenicity [25]. Previous studies [25] showed that the in vitro administration of more than 320 mg/ml of HA inhibited proliferation of murine melanoma cells by 50-90%. In particular, naturally occurring high levels of HA in colon cancer cells significantly inhibit the tumor growth [26].…”

Section: Discussionmentioning

confidence: 99%

Combined treatment of human MCF-7 breast carcinoma with antibody, cationic lipid and hyaluronic acid using ex vivo assays

Bartusik

Tomanek

Lattová

et al. 2010

Journal of Pharmaceutical and Biomedical Analysis

View full text Add to dashboard Cite

“…Later, when breast cancer research focused on HER-2, BT474 cells, which highly over-express this receptor, became very important as mimic for HER-2 driven disease [17–18]. Moreover, BT474 cells grow well in immunocompromised mice, making this cell line also valuable for in vivo xenograft studies [19–21]. …”

Section: Discussionmentioning

confidence: 99%

Long term storage in liquid nitrogen leads to only minor phenotypic and gene expression changes in the mammary carcinoma model cell line BT474

et al. 2017

View full text Add to dashboard Cite

Background/AimCancer cell lines are indispensible surrogate models in cancer research, as they can be used off-the-shelf, expanded to the desired extent, easily modified and exchanged between research groups for affirmation, reproduction or follow-up experiments.As malignant cells are prone to genomic instability, phenotypical changes may occur after certain passages in culture. Thus, cell lines have to be regularly authenticated to ensure data quality. In between experiments these cell lines are often stored in liquid nitrogen for extended time periods.Although freezing of cells is a necessary evil, little research is performed on how long-term storage affects cancer cell lines. Therefore, this study investigated the effects of a 28-year long liquid nitrogen storage period on BT474 cells with regard to phenotypical changes, differences in cell-surface receptor expression as well as cytokine and gene expressional variations.MethodsTwo batches of BT474 cells, one frozen in 1986, the other directly purchased from ATCC were investigated by light microscopy, cell growth analysis, flow cytometry and cytokine as well as whole-transcriptome expression profiling.ResultsThe cell lines were morphologically indifferent and showed similar growth rates and similar cell-surface receptor expression. Transcriptome analysis revealed significant differences in only 26 of 40,716 investigated RefSeq transcripts with 4 of them being up-regulated and 22 down-regulated.ConclusionThis study demonstrates that even after very long periods of storage in liquid nitrogen, cancer cell lines display only minimal changes in their gene expression profiles. However, also such minor changes should be carefully assessed before continuation of experiments, especially if phenotypic alterations can be additionally observed.

show abstract

Antitumor activity of Herceptin® in combination with STEALTH® liposomal cisplatin or nonliposomal cisplatin in a HER2 positive human breast cancer model

Cited by 26 publications

References 3 publications

Crystalline monoclonal antibodies for subcutaneous delivery

Crystalline monoclonal antibodies for subcutaneous delivery

Combined treatment of human MCF-7 breast carcinoma with antibody, cationic lipid and hyaluronic acid using ex vivo assays

Long term storage in liquid nitrogen leads to only minor phenotypic and gene expression changes in the mammary carcinoma model cell line BT474

Contact Info

Product

Resources

About